Table 1.
Demographic data of healthy controls (HC), end-stage renal disease patients (ESRD), and renal transplant recipients (Tx)
| HC (n = 31) |
ESRD (n = 18) |
Tx (n = 90) |
|
|---|---|---|---|
| Age (years, median, IQR) | 43 (35–54) | 65 (51–73) | 56 (45–63) |
| Sex (n, %) | |||
| Female | 17 (55) | 6 (33) | 27 (30) |
| Male | 14 (45) | 12 (67) | 63 (70) |
| Days post-transplant (median, IQR) | – | – | 410 (22–3452) |
| Type of donor (n, %) | |||
| Living | – | – | 17 (19) |
| Deceased | – | – | 73 (81) |
| Graft No. (n, %) | |||
| First | – | – | 82 (91) |
| Second | – | – | 7 (8) |
| Third | – | – | 1 (1) |
| Delayed graft function (n, %) | – | – | 9 (10) |
| Cold ischemia time (min, median, IQR) | – | – | 765 (485–984) |
| GFR ml/min (median, IQR) | – | – | 40 (24–55) |
| Serum creatinine (median, IQR) | – | – | 1.8 (1.3–2.8) |
| Previous CMV infection | – | – | 23 (26) |
| Previous BKVN (n, %) | – | – | 3 (3) |
| Patients with previous rejection (n, %) | |||
| Yes | – | – | 26 (29) |
| No | – | – | 64 (71) |
| Protein/creatinine ratio g/mol (median, IQR) | – | – | 24 (13–48) |
| CRP mg/l (median, IQR) | – | – | 10 (2–26) |
| Etiology of the end stage renal disease (n, %) | |||
| Chronic glomerulonephritis | – | 6 (33) | 32 (36) |
| Diabetes | – | 4 (22) | 11 (12) |
| Hypertension/ischemic | – | – | 4 (4) |
| ADPKD | – | 2 (11) | 10 (11) |
| Hereditary/ congenital | – | 1 (6) | 8 (9) |
| Others | – | 3 (17) | 15 (17) |
| Unknown | – | 2 (11) | 10 (11) |
| Induction immunosuppression (number and percentage) | |||
| Basiliximab | 77 (85.6) | ||
| ATG | 13 (14.4) | ||
| Maintenance immunosuppression (number and percentage of patients) | |||
| Ciclosporine | – | – | 41 (46) |
| Tacrolimus | – | – | 44 (49) |
| MMF | – | – | 75 (83) |
| Steroids | – | – | 86 (96) |
| Everolimus | – | – | 3 (3) |
| Azathioprine | – | – | 1 (1) |
Abbreviations: HC Healthy control, ESRD End-stage renal disease, Tx Transplant recipients, IQR Interquartile range, CMV Cytomegalovirus, BKVN Polyoma virus nephropathy, GFR Glomerular filtration rate, ADPKD Autosomal dominant polycystic kidney disease, MMF Mycophenolate mofetil